Home
About Us
Product Portfolio
News & Media
Careers

December 23, 2009 - Company Release
Forest Laboratories Announces Acquisition of Additional Rights Related to NXL 104, a Novel Broad-Spectrum Beta-Lactamase Inhibitor

September 12, 2009 - Company Release
Forest Laboratories Presents Analysis of Two Positive Pivotal Phase III Studies of Ceftaroline for the Treatment of Community-Acquired Pneumonia (CAP) at ICAAC

August 12, 2009 - Company Release
Forest Laboratories and AstraZeneca to Co-Develop and Commercialize a Late Stage Next Generation Anti-Infective

June 19, 2009 - Company Release
Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization

October 27, 2008 - Company Release
Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA

June 19, 2008 - Company Release
Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections

January 22, 2008 - Company Release
Novexel and Forest Laboratories Announce License Agreement for NXL 104, a Novel Broad-Spectrum Beta Lactamase Inhibitor

  • News & Media
  • Press Release Archive
  • Home

Copyright 2006-2010 Cerexa, Inc. All Rights Reserved   Legal Disclaimer | Privacy Statement | Site Map | Contact Us


85-1015517    09/09